Clinical Study to Compare Various Dosing and Titration Guidelines of Insulin Delivered Via V-Go ® in Patients With Type 2 Diabetes Initiating Basal Bolus Therapy in Primary Care Offices

Inclusion Criteria: Patients must meet all of the following inclusion criteria to be eligible for enrollment into the study: * Age ≥ 21 and ≤80 at time of study enrollment * Ability to read and understand English * BMI ≥ 25 kg/m2 * Weight less than or equal to 300 pounds. * A1C ≥8 but ≤12% (most recent value within 4 weeks of baseline visit) * Currently using any basal insulin therapy (NPH, Levemir, Lantus) with total daily dose of 30 to 120 units, and where basal dose is greater than the patient's BMI # * Willing to attend their physician's office for follow-up visits * Willing and able to understand and sign a written informed consent form (ICF) indicating that they agree to participate and have been informed of all pertinent aspects of the study * Must be willing to take and record at least 3 glucose measurements per time period (pre-breakfast, lunch, dinner and bed) per week. * Willing to opt-in into Valeritas Customer Care so that they can receive device support and reminders throughout the study * Most recent primary care office visit at one of the participating sites. Exclusion Criteria:Patients presenting with any the following exclusion criteria will not be eligible for enrollment into the study: * Patient with confirmed Type 1 diabetes and/or patients with a weight greater than 300 lbs. * Diagnosis of an Autoimmune disease affecting metabolism * Currently using GLP-1 medications * Current (within the last 6 months) or planned use of insulin pump for diabetes management or the use of U500 insulin. * Ongoing participation in any clinical study * Pregnant, lactating or intending to become pregnant * Current chronic systemic steroid use * Prior V-Go use